{"DataElement":{"publicId":"7797432","version":"1","preferredName":"Common Toxicity Criteria for Adverse Events Speech Disorder Type","preferredDefinition":"A description of the speech disorder common toxicity criteria adverse event.","longName":"7797429v1.0:7797431v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7797429","version":"1","preferredName":"Common Toxicity Criteria for Adverse Events Speech Disorder","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event._A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","longName":"2480706v1.0:7797427v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7797427","version":"1","preferredName":"Speech Disorder","preferredDefinition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","longName":"C5041","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Speech Disorder","conceptCode":"C5041","definition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDD97440-4795-5F2C-E053-4EBD850A273E","latestVersionIndicator":"Yes","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"ONEDATA","dateModified":"2021-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDD97440-47A6-5F2C-E053-4EBD850A273E","latestVersionIndicator":"Yes","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"BOLTONE","dateModified":"2022-02-16","changeDescription":"EB 2/16/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7797431","version":"1","preferredName":"Speech Disorder Type","preferredDefinition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders._Something distinguishable as an identifiable class based on common qualities.","longName":"7797431v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dysphasia","valueDescription":"Dysphasia","ValueMeaning":{"publicId":"2944377","version":"1","preferredName":"Dysphasia","longName":"2944377","preferredDefinition":"Impairment of verbal communication skills, often resulting from brain damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysphasia","conceptCode":"C35546","definition":"Impairment of verbal communication skills, often resulting from brain damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7431FEA7-FB26-A5C9-E040-BB89AD4324B4","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDD97DCD-1673-1E27-E053-4EBD850A18D9","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"ONEDATA","dateModified":"2021-10-08","deletedIndicator":"No"},{"value":"Aphasia","valueDescription":"Aphasia","ValueMeaning":{"publicId":"5189700","version":"1","preferredName":"Aphasia","longName":"5189700","preferredDefinition":"Impairment of the expression or comprehension of verbal and written language.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aphasia","conceptCode":"C34393","definition":"Impairment of the expression or comprehension of verbal and written language.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EA58DEF-E1E9-946E-E050-BB89AD43300B","latestVersionIndicator":"Yes","beginDate":"2016-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDD97DCD-167D-1E27-E053-4EBD850A18D9","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"ONEDATA","dateModified":"2021-10-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7797430","version":"1","preferredName":"Speech Disorder Type","preferredDefinition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.:Something distinguishable as an identifiable class based on common qualities.","longName":"C5041:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Speech Disorder","conceptCode":"C5041","definition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDD97DCD-164C-1E27-E053-4EBD850A18D9","latestVersionIndicator":"Yes","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"ONEDATA","dateModified":"2021-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDD97DCD-165D-1E27-E053-4EBD850A18D9","latestVersionIndicator":"Yes","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"MALUMK","dateModified":"2022-02-14","changeDescription":"Released. 02/14/2022 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CPST_TOX_speech_impair_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the speech disorder","type":"Preferred Question Text","description":"What was the speech disorder common toxicity criteria adverse event?","url":null,"context":"NHLBI"},{"name":"Specify type of speech impairment","type":"Application Standard Question Text","description":"Specify type of speech impairment","url":null,"context":"NHLBI"},{"name":"Specify type of speech impairment","type":"Alternate Question Text","description":"Specify type of speech impairment","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDD97440-47BC-5F2C-E053-4EBD850A273E","latestVersionIndicator":"Yes","beginDate":"2021-10-08","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-08","modifiedBy":"KUMMEROA","dateModified":"2022-06-07","changeDescription":"EB 2/16/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}